ALEC ALECTOR

Alector to Participate in Upcoming Healthcare Conferences

Alector to Participate in Upcoming Healthcare Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in the following upcoming investor conferences:

  • TD Cowen 45th Annual Health Care Conference (Boston, Massachusetts)
    • Tuesday, March 4, 2025, at 9:10 a.m. ET, corporate presentation
  • Leerink Partners Global Biopharma Conference (Miami, Florida)
    • Tuesday, March 11, 2025, at 8:40 a.m. ET, corporate presentation
  • Stifel 2025 Virtual CNS Forum
    • Tuesday, March 18, 2025, at 2:00 p.m. ET, corporate presentation

A webcast of each conference presentation will be available on the “Events & Presentations” page within the Investors section of the Alector website at . Replays of the webcasts will be available on the Alector website for 90 days following the presentation dates.

About Alector

Alector is a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology and neuroscience, the company is advancing a portfolio of genetically-validated programs that aim to remove toxic proteins, replace deficient proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector’s product candidates seek to treat a range of indications, including frontotemporal dementia, Alzheimer’s disease, Parkinson's disease, and Lewy body dementia. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being selectively applied to its next-generation product candidates and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit .

Alector Contacts:

Alector

Katie Hogan

(202) 549-0557

Argot Partners (media)

David Rosen

(212) 600-1494

Argot Partners (investors)

Laura Perry

(212) 600-1902



EN
25/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALECTOR

 PRESS RELEASE

Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 ...

Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer’s Disease --76-week trial is evaluating the safety and efficacy of a progranulin-elevating candidate in slowing disease progression-- --Enrollment completed ahead of schedule-- SOUTH SAN FRANCISCO, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced the completion of enrollm...

 PRESS RELEASE

Alector Provides Executive Leadership Update

Alector Provides Executive Leadership Update --Giacomo Salvadore, M.D., appointed Chief Medical Officer-- --Gary Romano, M.D., Ph.D., to transition from Chief Medical Officer role-- SOUTH SAN FRANCISCO, Calif., March 28, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that Gary Romano, M.D., Ph.D., has made the decision to step down from his role as Chief Medical Officer. Dr. Romano will continue to contribute to the company a...

 PRESS RELEASE

Alector Reports Fourth Quarter and Full Year 2024 Financial Results an...

Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025 Anticipate completing enrollment in the PROGRESS-AD Phase 2 clinical trial of AL101/GSK4527226 in participants with early Alzheimer’s disease by mid-2025 Applying Alector Brain Carrier to advance therapeutic candidates, including those targeting amyloid beta and replacing GCase $413.4 million in cash, cash equivalents and investments provide runway through 2026 Management to host co...

 PRESS RELEASE

Alector to Participate in Upcoming Healthcare Conferences

Alector to Participate in Upcoming Healthcare Conferences SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in the following upcoming investor conferences: TD Cowen 45th Annual Health Care Conference (Boston, Massachusetts) Tuesday, March 4, 2025, at 9:10 a.m. ET, corporate presentation Leerink Partners Global Biopharma Conference (Miami, Florida) Tu...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch